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ABSTRACT 
 
RNA interference (RNAi) is a widely used molecular biology technique to investigate the importance of 
specific genes in molecular pathways. Since mammalian cells are equipped with endogenous RNAi 
processing machinery, it has become common practice to transfect constructs that encode for short hairpin 
RNAs that are then cleaved to form the active RNAi sequences that bind to target mRNAs. Given the profit 
potential of this research approach, companies have developed retroviral libraries of shRNA constructs 
targeting the majority of the human genes. Recent technologic advances have allowed the rapid improvement 
of the vectors carrying the shRNA constructs while the silencing sequences remain the same. Therefore, sub-
cloning of shRNA sequences from more obsolete vectors to newer vectors is a straightforward way to take 
advantage of newer delivery technologies. We describe here a streamlined procedure to transfer shRNA 
sequences from the pSM2 retroviral vector to a newer pGIPZ vector that is more stable, contains a GFP 
cassette and allows the preparation of high titer viral particles for transduction of cells and in vivo use. We 
demonstrate that our protocol provides a cost-effective and fast method to successfully sub-clone shRNA 
from a pSM2 retroviral vector to a pGIPZ lentiviral vector making it a useful tool for the investigators that 
have purchased pSM2 vectors in the past and wish now to upgrade their constructs by inserting them in more 
versatile vectors. 
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INTRODUCTION 
 
RNA interference (RNAi) is an endogenous system that 
regulates gene expression. Since its discovery (Fire et al, 
1998) it has been exploited to silence specific genes and 
has become an important experimental method utilized in 
cellular and in vivo studies. RNAi based therapies are in 
development (Castanotto and Rossi, 2009). Given this 
promise and utility, many current investigations aim at 
better understanding the molecular mechanisms of RNAi 
and to find effective delivery methods for RNAi 
reagents. 
 
There are several approaches to introduce silencing RNAs 
into cells. One of them is to directly introduce short 
interfering RNAs, 21-23 nucleotide duplexes targeting 
specific mRNAs, into the cells or tissue under 
investigation (Elbashir et al, 2001). The disadvantage of 
this approach is that silencing is dependent on the amount 
of siRNA administered. A sustained silencing requires a 
constant and expensive siRNA supply. This shortcoming is 
eliminated when vectors containing sequences encoding 
short hairpin RNAs (shRNAs) are utilized (Paddison et al, 
2002). shRNAs are processed in the cells to produce 412 
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siRNA. Cells transfected with these vectors can sustain 
RNAi-mediated gene silencing for 48 hours or longer 
under antibiotic selection. 
 
The first large library of shRNA constructs targeting 
human and mouse genes was created in a retroviral vector, 
pShagMagic2 (pSM2) (Paddison et al, 2004). This vector 
is subject to frequent recombination, does not contain a 
GFP marker and has inefficient viral packaging that limits 
the use in hard to transfect cells and in vivo.  
 
Aware of these problems, companies have transferred the 
shRNAs into more stable GFP-tagged lentiviral vectors 
that produce high-titer viruses (Moffat et al, 2006). 
Lentiviruses are suitable for transduction of hard to 
transfect cell lines, primary cells and in vivo applications. 
The latest generation of lentiviral constructs includes 
inducible shRNA production (TRIPZ Lentiviral Inducible 
shRNAmir Library
®, www.openbiosystems.com). 
 
All the researchers who purchased the now outdated 
retroviral libraries cannot take advantage of these 
improvements. It is very expensive for laboratories to buy 
a complete lentiviral library, and the single lentiviral 
constructs range from $209 to $428. One inexpensive way 
to “upgrade” the shRNA without purchasing new ones is 
to sub-clone them to an appropriate lentiviral vector. Open 
Biosystems
® provides a protocol for sub-cloning shRNA 
constructs from pSM2 into the lentiviral vector pGIPZ but 
it requires expensive kits and multiple steps. Therefore, if 
an investigator wants to sub-clone a high number of 
shRNA constructs, it may be cheaper and more convenient 
to just purchase the constructs. 
 
We developed a protocol that greatly simplifies the 
transfer of shRNA sequences from the retroviral pSM2 
vector into the pGIPZ lentiviral vector. The improvements 
in the protocol are reported in Table 1. This sub-cloning 
protocol can be applied to sub-clone shRNA from pSM2 
to newer lentiviral vectors and possibly to sub-cloning 
schemes that involve plasmids and fragments of the same 
sizes reported here. 
 
 
MATERIALS AND METHODS 
 
Vector preparation and restriction digestion 
pSM2 and pGIPZ plasmids were purified with Qiagen 
Miniprep kits and DNA concentration was measured 
spectrophotometrically. All the restriction enzymes, the T4 
DNA ligase and the molecular weight markers were 
purchased from New England Biolabs. The Open 
Biosystems protocols were followed for bacterial culture 
growth and for recombination checks. 
 
pGIPZ vector (5-10μg) was digested with Mlu I/Xho I (1-
2U/μl) and the 13,087kb band was gel purified 
(QIAquick
® gel extraction kit, Qiagen). The elution step 
was performed with 50μl HPLC water. The purified vector 
was used immediately after heat-inactivation, or stored 
frozen at -20
oC until further use. The pSM2 vector (4μg) 
containing the shRNA of choice was also digested with 
Mlu I/Xho I (1-2U/μl) to generate a ~350bp fragment 
containing the shRNA, in a 20μl reaction volume (final 
insert concentration of 200ng/μl). After heat-inactivation 
(65°C for 20min) the cut pSM2 was used directly in 
ligation without purification. 
 
 
Table 1. Comparison between the Open Biosystems
® and the proposed streamlined sub-cloning protocols for insert preparation. 
Cost- and time-savings are detailed for steps in insert preparation that are significantly different and are estimated for the smallest 
sized kit/reagent. In summary, an investigator with pSM2 vectors available can sub-clone a single construct for $631 using the Open 
Biosystems
® protocol or $256 using our streamlined protocol. For both protocols there is an additional one-time expense of 
purchasing the empty pGIPZ vector ($321). In summary, our simplified procedure provides approximately 60% cost savings 
compared to the protocol provided by Open Biosystems
® and is faster. Alternatively, an investigator can purchase the pGIPZ shRNA 
clones for $209 each, as well as the required pGIPZ control shRNAs ($428 each). 
 
Original Open Biosystems
® Protocol  Streamlined Protocol 
Step  
  Materials / Reagents 
 
Time 
 
Cost 
Step  
  Materials / Reagents 
 
Time
 
Cost
Primers for pSM2 shRNA PCR:                                             
pSM2 forward - 5' aagccctttgtacaccctaagcct 3'                            
pSM2 reverse - 5' actggtgaaactcacccagggatt 3’ 
 
 
1-3d 
 
 
 $14 
Not required     
 
4 PCR amplifications per shRNA to be sub-cloned             
       KOD Hot start Polymerase Kit
®, Novagen
® 
 
 
2-3hr 
 
 
 $50 
Not required    
 
Restriction digest Mlu I/Xho I  3hr  $121  Restriction digest Mlu I/Xho I  3 hr   $121 
 
Agarose gel Electrophoresis   45min     Not Required       
 
Gel purification/quantitate fragment concentration        
     Wizard SV Gel /PCR Clean-up System column, Promega
®         30min   $83   Not required       
 
Ligation (250ng destination vector)  3hr   $63  Ligation (100 ng destination vector)  3hr   $63 
 
Transformation                                                                 
      Prime+ competent E. coli, Gentaur
®    $300 
Transformation  
     DH5-alpha E. coli, InVitrogen
®       $72 
 
TOTAL COSTS     $631      $256   413 
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Ligation and transformation 
Experimental and control ligation mixes were set up in 
10μl final volume using 1:1 molar ratios of the destination 
vector:insert (100ng vector and 2.6ng insert). 100ng of the 
uncut pGIPZ vector was used as a positive control diluted 
in ligation buffer, 100ng of the Xho I/Mlu I pGIPZ cut 
vector without ligase was used to control for cutting 
efficiency of both enzymes and 100ng of the Xho I/Mlu I 
pGIPZ cut vector with 1μl of ligase were used to control 
for re-ligation of partially cut pGIPZ vector. In addition 
we had a ligation reaction without DNA added to control 
for DNA contamination in our reagents.    
 
Ligation was performed at room temperature for 3hr to 
overnight and was followed by heat-inactivation at 65
oC 
for 20min. 1μl of ligation mix was transformed in DH5α 
cells (InVitrogen). 300μl of the bacterial suspension were 
plated onto LB-ampicillin plates. Plates were incubated 
over night at 37
oC. The next morning, colonies on the 
plates were counted to verify successful ligation. Typical 
observed colony counts were as follows: More than 100 
colonies on the pGIPZ positive control and 20-100 
colonies on the experimental ligation or ligations. The 
pGIPZ vector cut without ligase had generally 0-10 
colonies while the pGIPZ cut vector added with ligase had 
0-20 colonies. 
 
Clone selection and verification 
The ratio between the number of colonies on the 
experimental plates and the control plate (cut pGIPZ 
vector with ligase) was calculated and multiplied by three, 
the resulting number of colonies was selected for 
screening to validate our method. Each colony picked was 
dissolved in 10μl sterile HPLC water. 5μl of this 
suspension were used to inoculate a 5ml liquid culture of 
LB-ampicillin, 2μl were dotted on a master LB-Amp plate, 
and 2μl used as template for  PCR to confirm shRNA 
insertion. The PCR amplification products are 600bp if the 
shRNA sequence is present and 500bp if it is not. The 
following PCR parameters were used: 5min at 94
oC; then 
30 cycles of, 94
oC for 15sec, 56
oC for 30sec, 72
oC for 
25sec. The pGIPZ-specific primers used were: 
 
X76 Forward: 5'ACGTCGAGGTGCCCGAAGGA 
 
M100 Reverse: 5'AAGCAGCGTATCCACATAGCGT 
 
This PCR reaction only amplifies shRNA in pGIPZ vectors. 
 
In addition to the PCR check, the pGIPZ vectors 
containing the sub-cloned shRNA were also digested to 
check for recombination of the vectors and successful 
insertion of the shRNA sequence. Sac II digestion was 
used to test for recombination of the pGIPZ vectors 
containing the sub-cloned shRNAs (expected bands: 
7927bp, 2502bp and 1259bp). Successful ligation of the 
shRNA sequence was verified by excising it from the 
recipient pGIPZ vector using Mlu I/Xho I double digestion 
(expected bands: 350bp and ~10Kb).  
 
Knock-down and western blotting procedure 
SH-SY5Y cells over-expressing APP-Gal4 were 
transiently transfected or transduced as previously 
described (Zhang et al, 2007). Transfection was performed 
with pSM2 plasmids targeting APP or a non-silencing 
control (Open Biosystems), and with pGIPZ plasmids 
containing the same shRNA sequences as the pSM2 
vectors that were sub-cloned following our protocol. 
Transfection was performed with Arrrest-In
® (Open 
Biosystems
®) transfection reagent. Whole cell lysates were 
prepared in ice-cold radio immuno-precipitation buffer 
(150mM NaCl, 1%, v/v, NP40, 0.5%, v/v, DOC, 1%, w/v, 
SDS, 50mM Tris, pH 8.0) supplemented with Halt cocktail 
of protease and phosphatase inhibitors (ThermoFisher). 
The western blotting procedure has been previously 
described (Zhang et al, 2007). We used anti-APP antibody 
clone A8717 (Sigma) and anti-actin antibody (Sigma) at 
1:2000 and 1:15,000 dilution, respectively. The same cell 
line was transduced with viruses obtained following the 
packaging protocol provided by Open Biosystems
® but 
using the same sub-cloned pGIPZ vectors previously 
employed for the transfection. 
 
RESULTS AND DISCUSSION 
 
Our protocol was successfully used to sub-clone shRNA 
constructs into pGIPZ vectors. As an example, one 
experimental transformation plate had approximately fifty 
colonies, the control cut pGIPZ vector with ligase had 6 
colonies so the ratio of clones containing the insert to the 
empty ones was 50/6=8.3. Twenty-five colonies were 
screened with PCR using pGIPZ specific primers that 
amplify the shRNA sequence. In Figure 1A we show 16 of 
the 25 PCR reactions with the appropriate controls run on 
an agarose gel stained with ethidium bromide. Two clones 
did not show amplification (not shown), one clone resulted 
empty (Figure 1A; lane 4) and three clones showed sub-
optimal amplification (Figure 1A; lanes 13, 14, 15). All 
the remaining clones showed the correct band size with 
efficient amplification. In summary, out of the 25 colonies 
screened, only 3 did not show correct amplification 
confirming a ratio of 25/3=8.3 clones containing insert to 
the false positive ones. Following PCR we checked the 
recipient vectors for both recombination and the presence 
of the insert. In Figure 1B we show the results of Sac II 
restriction digestion of 16 clones that showed the correct 
amplicon following PCR. These 16 clones did not show 
signs of recombination. After checking for recombination 
of the recipient plasmid, we also checked for correct 
ligation of the shRNA sequence. In Figure 1C we used 
restriction digestion to excise the inserted shRNA from the 
clones and we confirmed the correct ligation in the new 
vector. All the clones that showed the correct PCR 
amplicon also showed correct restriction patterns making 
restriction digest unnecessary. Insertion of the shRNA 
sequences was also verified by sequencing. 
 
In order to ensure that our sub-cloned constructs main-
tained silencing activity, comparable to the original pSM2 
plasmids, we transfected, using the same procedure, both 
vectors in the same cell line. Moreover, we assessed if viral 
transduction of the cells also showed effective silencing. 
Figure 2 shows the detection of Amyloid Precursor Protein 
(APP) by western blotting in SH-SY5Y APP-Gal4 cells 
following transfection of shRNA constructs in pSM2 or 
pGIPZ vectors or transduction with pGIPZ containing viral 414 
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Figure 1. Gel electrophoresis analysis of PCR and restriction 
endonuclease-digested products of the putative clones. A. 
Successful subcloning was assessed by colony PCR, using 
pGIPZ specific PCR primers. 16 putative clones were picked 
from a transformation plate. The last two samples are a positive 
control (+) (a pGIPZ vector containing a shRNA sequence that 
had been previously verified by nucleotide sequencing) and the 
pGIPZ empty vector (E). Clone 4 does not contain the insert 
while clones 13, 14 and but showed inefficient PCR 
amplification. These PCR results confirm that the shRNA is 
inserted in the pGIPZ destination vector.  B. Sac II restriction 
endonuclease digest of positive clones identified in panel (A) 
shows no signs of pGIPZ recombination. We observe the 
expected bands: 7927bp, 2502bp and 1259bp. C. Mlu I/Xho I 
restriction digest shows the inserted 350bp band corresponding to 
the shRNA excised from the destination pGIPZ vector. 
 
 
 
   A:     B:     C: 
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Figure 2. Western blot analysis of cells transfected or transduced 
with shRNA constructs in different vectors. Knock-down of the 
Amyloid Precursor Protein (APP) is assessed in the human 
neuroblastoma cell line SH-SY5Y. APP is over-expressed in this 
cell line and is detected as two bands that are fully-glycosylated 
(top migrating band) and partially-glycosylated (lower migrating 
band) states of APP, respectively. The anti-human APP antibody 
A8717 was used. Actin levels were used as a loading control. A 
and B. Transfection of either pSM2 vectors (A) containing the 
shRNA targeting APP or pGIPZ vectors (B), containing the same 
shRNA construct, efficiently decreases APP total levels 
compared to non silencing control shRNA. C. APP levels are 
also efficiently decreased through transduction of the cells with 
viral particles obtained with the subcloned shRNA pGIPZ 
vectors. APP: Amyloid Precursor Protein; CTRL: non-silencing 
shRNA. 
particles. The silencing efficiency of the shRNA constructs 
in their original pSM2 vectors (Figure 2A) is comparable 
with the one of the shRNA subcloned in the pGIPZ vector 
(Figure 2B) showing that the construct was successfully 
inserted and does not loose targeting ability. Finally, we 
show that the pGIPZ construct can also efficiently 
decrease APP levels when delivered via viral particles 
(Figure 2C). 
 
CONCLUSIONS 
 
The RNAi Resource Center at Drexel University 
purchased from Open Biosystems the pSM2 retroviral 
library targeting ~65,000 human genes. Our sub-cloning 
method has been applied successfully to ~100 shRNA 
sequences of interest that were transferred from the pSM2 
vector into the pGIPZ empty vector. The protocol proved 
successful in the hands of different operators and 80% of 
the shRNA constructs were sub-cloned successfully on the 
first attempt. Unsuccessful sub-cloning was largely due to 
the presence of recombination in the pSM2 donor vectors.  
 
pGIPZ vectors containing shRNAs obtained from our 
subcloning procedure produced high titer viruses (10
6 
infectious units/ml) that were used to transduce hard-to-
transfect cell lines and primary neurons. We believe that 
our protocol will be helpful to all the investigators who 
have invested in the now outdated pSM2 libraries allowing 
them to efficiently upgrading their shRNA sequences into 
the new lentiviral vectors. Given the simplicity of the steps 
involved, it would probably be possible to implement high 
throughput methods to automate the rapid transfer of many 
shRNA simultaneously. This procedure offers 
approximately 60% cost savings and substantial time 
savings compared to the suggested protocol. 
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